EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

ChengDa Pharmaceuticals Co. Ltd. (301201) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of ChengDa Pharmaceuticals Co. Ltd. ¥5.07, price ¥30.49, upside -83.4%, quality 50 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · CN · ISIN CNE100005766

CP Thin data Sep 24, 2026

ChengDa Pharmaceuticals Co. Ltd.

301201 · SHE

Weakest SetupStrongly overvalued and low quality.

!Fair value ¥5.07 · Strongly overvalued (−83.4%)
!Quality 50/100
!Weak Growth (revenue 5y +1.7 %/yr)
!Loss-making · -0.8% net margin (TTM)
!Low debt · negative free cash flow
!0.7% dividend yield · Token dividend
!Mixed vs. peers (5/12)
!Narrow moat 26/100
!Evidence only low, so the estimate is less certain
!Weak on dividend: 13 out of 100
Watch ChengDa Pharmaceuticals Co. Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥85.72 ¥14.84 Fair Value ¥5.07 Jan 2022 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

56‑month range ¥14.84 – ¥85.72 · fair‑value band ¥4.47 – ¥5.14 · the ¥30.49 price screens above the ¥5.07 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow ChengDa Pharmaceuticals Co. in your weekly email

Every Wednesday you see whether ChengDa Pharmaceuticals Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally.

Show more

ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food and feed additives, such as L-carnitine and L-carnitine tartrate. The company also provides bulk drug products, including urogenital, nervous system, blood and hematopoietic organs, muscular system, digestive tract and metabolism, antineoplastic and immunomodulators; and pharmaceutical intermediates comprising drug intermediates for blood and hematopoietic organs, drug intermediates in digestive tract and metabolism, and nervous system drug intermediates. ChengDa Pharmaceuticals Co., Ltd. was founded in 1980 and is based in Jiaxing, China.

Stock analysis

ChengDa Pharmaceuticals Co. Ltd. (301201) currently trades at ¥30.49, while our model-based Fair Value estimate is ¥5.07, 83.4% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of ¥9.07 per share, and 0 of the 6 models we run sit above the ¥30.49 price.

Bear case: the Earnings-Based group reads lowest at ¥5.03, and 6 of the 6 models stay below the price. Evidence for this calculation is low.

Scenario range: ¥4.47 (bear) to ¥5.14 (bull), the price of ¥30.49 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

ChengDa Pharmaceuticals Co. Ltd. reported revenue of 406M CNY in FY2025 versus 416M CNY in FY2021, a compound −0.6%/yr. Reported net income was −11.9M CNY in FY2025.

Key figures

Market cap 5.4B CNY (≈ $802M) · P/S ratio 11.7 · EPS (TTM) ¥−0.0200 · Dividend yield 0.7% · Net margin −2.9% · Return on equity −0.2% · Return on assets (EBIT) 4.5% · Operating margin 4.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).

What moves the price

The share trades about 51% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −83%, 301201 screens richer than that median.

Fair Value models

Bear ¥4.47 Fair Value ¥5.07 Bull ¥5.14
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
ROIC Compounder ¥4.96 ¥5.03 ¥5.09 72
EPV ¥4.96 ¥5.03 ¥5.09 71
EV/EBITDA ¥10.27 ¥12.23 ¥14.18 67
All 6 models by family
Earnings-Based
EPV ¥4.96 ¥5.03 ¥5.09 71
Multiples
EV/EBIT ¥5.52 ¥5.89 ¥6.26 66
EV/EBITDA ¥10.27 ¥12.23 ¥14.18 67
EV/Revenue ¥5.20 ¥5.54 ¥5.88 54
Asset-Based
NCAV (Graham) ¥6.77 ¥9.07 ¥13.54 54
Economic Profit
ROIC Compounder ¥4.96 ¥5.03 ¥5.09 72

Open the full fair value analysis →

Notify me when 301201 reaches fair value

Put 301201 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 50/100

Of which business quality 49 · Market factors (momentum, volatility) 33

Profitability 10
Margins and returns on capital today
Quality Growth 56
Are margins and returns improving?
Cashflow 13
Earnings quality: real cash, not paper profit
Fin. Strength 87
Balance sheet, leverage, solvency risk
Investment 72
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 27
Price trend over the last 3–12 months (market factor)
52W Momentum 25
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 15/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+22.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.7%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
27.9% (2020) → 3.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

301201 screens overvalued: fair value 83% below the price. Compare with Merck KGaA →

Compare ChengDa Pharmaceuticals Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 569 stocks

Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 50 · Below median
Fair Value upside −83.4% · Bottom 25%
Profitability
Return on assets −0.2% · Bottom 25%
Net margin (TTM) −0.8% · Below median
Operating margin (TTM) 4.1% · Below median
Growth and dividend
Revenue growth 68.1% · Top 25%
Dividend yield (TTM) 0.7% · Below median
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.38× · Cheapest 25%
P/S (TTM) 1.75× · Cheaper than median
EV/EBITDA 1.7× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 14
FUTURE (revenue growth)100 · sector 26
PAST (return on equity)0 · sector 29
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)13 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ChengDa Pharmaceuticals Co. Ltd. · Fair Value
¥5.07 −83%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "ChengDa Pharmaceuticals Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/301201

Frequently asked questions

Is ChengDa Pharmaceuticals Co. Ltd. (301201) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥5.07 versus a price of ¥30.49, about −83% upside (overvalued).
What is the fair value of 301201?
Our model-based fair value for ChengDa Pharmaceuticals Co. Ltd. is ¥5.07 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥30.49.
What is the quality score of 301201?
ChengDa Pharmaceuticals Co. Ltd. has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ChengDa Pharmaceuticals Co. Ltd. (301201)?
Our model-based price target is the fair value of ¥5.07 (as of Sep 24, 2026) from 6 valuation models. Cautious scenario ¥4.47, optimistic scenario ¥5.14. It is a calculation from audited fundamentals, not an analyst target.
What is the ChengDa Pharmaceuticals Co. Ltd. stock forecast for 2026?
Our models put fair value at ¥5.07, about −83% upside versus a price of ¥30.49 (overvalued). Cautious scenario ¥4.47, optimistic scenario ¥5.14. The calculation is refreshed regularly with new filings.
What is the revenue of ChengDa Pharmaceuticals Co. Ltd. (301201)?
ChengDa Pharmaceuticals Co. Ltd. reported trailing-twelve-month revenue of about 458M CNY (latest available figure, as of Sep 24, 2026).
Does ChengDa Pharmaceuticals Co. Ltd. pay a dividend?
ChengDa Pharmaceuticals Co. Ltd. currently shows a dividend yield of about 0.66% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of ChengDa Pharmaceuticals Co. Ltd. (301201)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ChengDa Pharmaceuticals Co. Ltd. it is ¥5.07 per share (as of Sep 24, 2026), against a price of ¥30.49. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is ChengDa Pharmaceuticals Co. Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 301201 trades above its calculated fair value: price ¥30.49, fair value ¥5.07, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 301201?
No. The price is what the market pays today (¥30.49); the fair value is what the company's own numbers justify (¥5.07). For ChengDa Pharmaceuticals Co. Ltd. the two are ¥25.42 per share apart. That gap is exactly why we show both numbers side by side.
How much is ChengDa Pharmaceuticals Co. Ltd. worth?
The market values ChengDa Pharmaceuticals Co. Ltd. at about 5.4B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥30.49; our models calculate a fair value of ¥5.07 per share.
What do the bullish and bearish scenarios say about 301201?
Our models span a range for ChengDa Pharmaceuticals Co. Ltd.: cautious scenario ¥4.47, base ¥5.07, optimistic ¥5.14 per share (as of Sep 24, 2026, price ¥30.49). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ChengDa Pharmaceuticals Co. Ltd. (301201)?
Balance-sheet figures for ChengDa Pharmaceuticals Co. Ltd. (as of Sep 24, 2026): return on equity −0.2%, debt of 0.02 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 301201 from its 52-week high?
ChengDa Pharmaceuticals Co. Ltd. trades at ¥30.49, about 51% below its 52-week high of ¥62.41 and 13% above the low of ¥27.08 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of ¥5.07 is for.
Which stocks are comparable to ChengDa Pharmaceuticals Co. Ltd.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ChengDa Pharmaceuticals Co. Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price ¥30.49, calculated fair value ¥5.07 (−83%), Quality Score 50/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 301201 calculated?
We run ChengDa Pharmaceuticals Co. Ltd. through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥5.07, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. ChengDa Pharmaceuticals Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ChengDa Pharmaceuticals Co. Ltd. (301201)?
The closing price on Sep 30, 2026 was ¥30.49. Our model-based fair value is ¥5.07, about −83% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ChengDa Pharmaceuticals Co. Ltd. right now?
The price sits above even our optimistic bull case (¥5.14). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (¥4.47 to ¥5.14), unusually little disagreement for a valuation.

Key figures of ChengDa Pharmaceuticals Co. Ltd.

How large is the market capitalisation of ChengDa Pharmaceuticals Co. Ltd. (301201)?
The market capitalisation of ChengDa Pharmaceuticals Co. Ltd. is 5.4B CNY (≈ $802M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ChengDa Pharmaceuticals Co. Ltd. (301201)?
The price-to-sales ratio of ChengDa Pharmaceuticals Co. Ltd. is 11.7 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ChengDa Pharmaceuticals Co. Ltd. (301201)?
Earnings per share at ChengDa Pharmaceuticals Co. Ltd. are ¥−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of ChengDa Pharmaceuticals Co. Ltd. (301201)?
The dividend yield of ChengDa Pharmaceuticals Co. Ltd. is 0.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of ChengDa Pharmaceuticals Co. Ltd. (301201)?
The net margin of ChengDa Pharmaceuticals Co. Ltd. is −2.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ChengDa Pharmaceuticals Co. Ltd. (301201)?
The return on equity (ROE) of ChengDa Pharmaceuticals Co. Ltd. is −0.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ChengDa Pharmaceuticals Co. Ltd. (301201)?
On an EBIT basis the return on assets of ChengDa Pharmaceuticals Co. Ltd. is 4.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ChengDa Pharmaceuticals Co. Ltd. (301201)?
The operating margin of ChengDa Pharmaceuticals Co. Ltd. is 4.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ChengDa Pharmaceuticals Co. Ltd. (301201)?
Revenue at ChengDa Pharmaceuticals Co. Ltd. is growing +68.1% versus a year earlier (3y avg −0.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ChengDa Pharmaceuticals Co. Ltd. (301201)?
Earnings per share at ChengDa Pharmaceuticals Co. Ltd. are growing −74.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does ChengDa Pharmaceuticals Co. Ltd. (301201) generate?
The free cash flow of ChengDa Pharmaceuticals Co. Ltd. is −35.0M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ChengDa Pharmaceuticals Co. Ltd. (301201) carry?
The net debt of ChengDa Pharmaceuticals Co. Ltd. is 35.6M CNY (fiscal year 2021). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch ChengDa Pharmaceuticals Co. Ltd. in the live analysis

One click puts ChengDa Pharmaceuticals Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.